Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …

Antibodies are considered as an excellent foundation to neutralize pathogens and as highly
specific therapeutic agents. Antibodies are generated in response to a vaccine but little use …

The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
Several vaccine approaches and repurposed drugs are currently under evaluation for safety …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …

To address the COVID-19 pandemic, there has been an unprecedented global effort to
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …

The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …

The devastating economic and public health consequences caused by the COVID-19
pandemic have prompted outstanding efforts from the scientific community and …

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) threatens global public health and …